Literature DB >> 25478411

The effect of antenatal L-arginine and antioxidant supplementation on oxidative stress marker levels in newborns.

Shweta Dr1, Anuradha Khanna2.   

Abstract

INTRODUCTION: The present study was conducted in the Department of Obstetrics, Paediatrics & Biophysics IMS, BHU, Varanasi with an aim to study the role of L-arginine and oral antioxidants as a part of therapy in patients diagnosed with IUGR (Intra uterine growth restriction ) and cord serum NO and oxidative stress markers GSH and SOD in newborns following delivery of such patients.
MATERIALS AND METHODS: The study included 40 pregnant patient between 30-32 weeks of gestation diagnosed with IUGR who were divided into 3 groups: Group I (treated with L-arginine N=10), Group II (treated with antioxidants N=10), Group III (without nutritional supplementation N=10) and Group IV (healthy control pregnant patients of same gestational age range N=10) were taken. Cord serum NO & oxidative stress markers (GSH & SOD) were measured following delivery of patients from those four groups.
RESULTS: The cord serum NO levels (μmol/lt) showed a significant increase & SOD (U/ml) & GSH (U/lt) values were increased in newborns to mothers diagnosed with IUGR after treatment with L-arginine. Similar results were obtained for treatment with antioxidants.
CONCLUSION: The reduced NO & reduced cord serum circulating levels of oxidative stress markers (GSH & SOD) activity may play an important role in the occurrence of IUGR.

Entities:  

Keywords:  Antioxidants; L- arginine

Year:  2014        PMID: 25478411      PMCID: PMC4253229          DOI: 10.7860/JCDR/2014/8343.4966

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  9 in total

1.  L-Arginine treatment for asymmetric fetal growth restriction.

Authors:  X M Xiao; L P Li
Journal:  Int J Gynaecol Obstet       Date:  2005-01       Impact factor: 3.561

2.  [Use of arginine in intruterine growth retardation (IUGR). Authors' experience].

Authors:  C Lampariello; A De Blasio; A Merenda; E Graziano; A Michalopoulou; P Bruno
Journal:  Minerva Ginecol       Date:  1997-12

3.  Intrauterine growth and spastic cerebral palsy II. The association with morphology at birth.

Authors:  E Blair; F Stanley
Journal:  Early Hum Dev       Date:  1992-02       Impact factor: 2.079

4.  Vitamin C and E supplementation in women at risk of preeclampsia is associated with changes in indices of oxidative stress and placental function.

Authors:  Lucy C Chappell; Paul T Seed; Frank J Kelly; Annette Briley; Beverley J Hunt; D Stephen Charnock-Jones; Anthony Mallet; Lucilla Poston
Journal:  Am J Obstet Gynecol       Date:  2002-09       Impact factor: 8.661

Review 5.  Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia.

Authors:  J M Roberts; R N Taylor; A Goldfien
Journal:  Am J Hypertens       Date:  1991-08       Impact factor: 2.689

6.  NO modulates fetoplacental blood flow distribution and whole body oxygen extraction in fetal sheep.

Authors:  J J Smolich
Journal:  Am J Physiol       Date:  1998-05

Review 7.  Free radical-lipid interactions and their pathological consequences.

Authors:  C Rice-Evans; R Burdon
Journal:  Prog Lipid Res       Date:  1993       Impact factor: 16.195

8.  Effects of L-arginine on utero-placental circulation in growth-retarded fetuses.

Authors:  I Neri; V Mazza; M C Galassi; A Volpe; F Facchinetti
Journal:  Acta Obstet Gynecol Scand       Date:  1996-03       Impact factor: 3.636

9.  Oxidative stress in term small for gestational age neonates born to undernourished mothers: a case control study.

Authors:  Piyush Gupta; Manish Narang; B D Banerjee; Srikanta Basu
Journal:  BMC Pediatr       Date:  2004-07-20       Impact factor: 2.125

  9 in total
  1 in total

1.  Protective effects of compound ammonium glycyrrhizin, L‑arginine, silymarin and glucurolactone against liver damage induced by ochratoxin A in primary chicken hepatocytes.

Authors:  Zugong Yu; Feng Wu; Jing Tian; Xuewen Guo; Ran An
Journal:  Mol Med Rep       Date:  2018-07-16       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.